AstraZeneca stock after-hours at EUR 143.58: minus 1.05 percent versus the prior close
Published on 09/30/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock was at EUR 143.58 after-hours at 7:14 p.m. CEST on September 30, 2026, down 1.05 percent versus the Lang & Schwarz prior close of EUR 145.10. The quote was separate from the company developments reported below.
Trading day in Frankfurt
The Lang & Schwarz after-hours price was EUR 143.58, compared with the prior close of EUR 145.10. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Summit investment and bladder-cancer review
In a release published September 28, AstraZeneca said it had agreed to invest $2 billion in newly issued equity in Summit Therapeutics to accelerate development of ivonescimab with antibody-drug conjugates. The companies also agreed to evaluate AstraZeneca’s sonesitatug vedotin with ivonescimab in gastrointestinal cancers. AstraZeneca said it would receive rights equivalent to approximately 12.0 percent of Summit’s outstanding common stock after completion, or approximately 10.6 percent on a fully diluted basis. Closing was anticipated within one week, subject to customary regulatory clearances. AstraZeneca provided the details.
In a September 25 release, AstraZeneca said the U.S. Food and Drug Administration had accepted and granted Priority Review to its supplemental Biologics License Application for Imfinzi with enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for or have declined cisplatin-based chemotherapy. The company said the FDA decision was anticipated during the fourth quarter of 2026. AstraZeneca said the application was based on results from the Phase III VOLGA trial.
